Tech Company Financing Transactions
Antheia Funding Round
Antheia, based in Menlo Park, raised $56 million in investment from Global Health Investment Corporation, ATHOS KG and Civilization Ventures.
Transaction Overview
Company Name
Announced On
6/3/2025
Transaction Type
Venture Equity
Amount
$56,000,000
Round
Series C
Investors
Proceeds Purpose
The new financing will be used to expand commercialization of Antheia's first product, thebaine, and launch additional products from the company's pipeline of 70+ biosynthetic pharmaceutical ingredients, which spans seven therapeutic areas and prioritizes essential medicines in or at risk of shortage. Additionally, the funding will allow Antheia to unlock its U.S. manufacturing operations to meet domestic demand and begin new strategic innovation programs in Singapore, while expanding into the broader Asia region.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1430 O'Brien Dr. A
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Overview
Antheia combines founding intellectual property with world-leading expertise in synthetic biology, informatics, and fermentation technology to provide a stable and cost-competitive supply of plant-based medicines and to transform the discovery, manufacture, and distribution of medicines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christina Smolke
Chief Scientific Officer
Kristy Hawkins
VP - Bus. Development
Yen-Hsiang Wang
Browse more venture capital transactions:
Prev: 6/3/2025: myLaurel venture capital transaction
Next: 6/3/2025: Canid venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs